Breaking News, Financial News

Financial Report: Biogen Idec 3Q

Biogen Idec

3Q Revenues: $1.1 billion (+38%)

3Q Earnings: $207 million (+74%)

YTD Revenues: $3.0 billion (+33%)

YTD Earnings: $576.5 million (+32%)

Comments: Tysabri sales recorded by Biogen, based on its collaboration with Elan, were $171 million (+172%) in the quarter. This consisted of $56 million related to product sold through Elan in the U.S. (based on $122 million of in-market sales); and $115 million related to product sold by Biogen internationally. Avonex sales were up 26% to $573 million. Rituxan sales were up 27% to $299 million (co-marketed in the U.S. with Genentech). R&D expenses were $269 million in the quarter (-6%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters